The U.S. Food and Drug Administration (FDA) announced Friday that it will have its advisory panel meet to discuss Novavax’s request for emergency use authorization (EUA) of its COVID-19 vaccine in June.
“On June 7, FDA intends to convene VRBPAC [Vaccines and Related Biological Products Advisory Committee] to discuss an EUA request for a COVID-19 vaccine manufactured by Novavax to prevent COVID-19 in individuals 18 years of age and older,” the federal regulatory agency said in a press release.
Novavax, a biotechnology company based in Maryland, submitted an EUA for its COVID-19 vaccine known as NVX-CoV2373 on Jan. 31, 2022.
Despite Novavax being awarded $1.6 billion by the United States government in July 2020 to support the testing, commercialization, and manufacture of a possible COVID-19 vaccine in the United States the federal health authorities have been slow to authorize its vaccine.
…